Amundi
OLMA icon

Amundi’s Olema Pharmaceuticals OLMA Stock Holding History

Amundi’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,839
Closed -$10.6K – 2232
2024
Q4 		$10.6K Hold
1,839
– – ﹤0.01% 1909
2024
Q3 		$21K Hold
1,839
– – ﹤0.01% 1905
2024
Q2 		$19.6K Buy
+1,839
New +$19.9K ﹤0.01% 1851

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

Amundi's OLMA Position: Q1 2025 in Review

Amundi sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 1,839 shares — an estimated $10.6K sold.

Amundi first reported a position in OLMA in Q2 2024 and held it in 3 quarters. The position peaked at $21K in Q3 2024. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

  • Amundi reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Amundi sold 1,839 Olema Pharmaceuticals shares in Q1 2025, an estimated $10.6K.
  • Amundi first reported a position in Olema Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Amundi's Olema Pharmaceuticals position peaked at $21K in Q3 2024.
  • 133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on Amundi's 13F filing for Q1 2025, filed 15 May 2025.